OTCMKTS:ADXS

Ayala Pharmaceuticals (ADXS) Stock Forecast, Price & News

$1.20

+0.20 (+20.00%)

(As of 05/31/2023 ET)

Compare

Today's Range: $1.10
▼
$1.20
50-Day Range: $0.65
▼
$1.29
52-Week Range: $0.65
▼
$7.20

Volume: 16,264 shs
Average Volume: 7,660 shs
Market Capitalization: $2.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Ayala Pharmaceuticals (OTCMKTS:ADXS) Stock

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

May 30, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Upgraded to "Buy" by LADENBURG THALM/SH SH

May 28, 2023 | americanbankingnews.com

Short Interest in Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Rises By 73.3%

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 25, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 23, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

May 22, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

May 20, 2023 | health.usnews.com

Armando Ayala

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.

May 13, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

May 12, 2023 | americanbankingnews.com

Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Sees Large Decrease in Short Interest

May 7, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

April 28, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

April 27, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 21, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Coverage Initiated at StockNews.com

April 20, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

April 13, 2023 | uk.finance.yahoo.com

Ayala Pharmaceuticals, Inc. (ADXS)

April 12, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Receives New Coverage from Analysts at StockNews.com

April 12, 2023 | forbes.com

Hubei Biocause Pharmaceutical

April 12, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Now Covered by StockNews.com

April 10, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Now Covered by Analysts at StockNews.com

April 7, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Earns Sell Rating from Analysts at StockNews.com

April 6, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Coverage Initiated by Analysts at StockNews.com

April 5, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)

April 4, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)

March 30, 2023 | americanbankingnews.com

Ayala Pharmaceuticals (OTCMKTS:ADXS) Research Coverage Started at StockNews.com

March 3, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

See More Headlines

ADXS Price History

30 days | 90 days | 365 days | Advanced Chart

ADXS Company Calendar

Last Earnings: 9/09/2021
Today: 6/01/2023
Next Earnings (Estimated): 6/06/2023
Fiscal Year End: 10/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ADXS
CUSIP: N/A
CIK: 1100397
Web: www.advaxis.com
Phone: (609) 452-9813
Fax: 609-452-9818
Employees: 14
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): ($8.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,360,000.00
Net Margins: N/A
Pretax Margin: -5,723.60%
Return on Equity: -57.87%
Return on Assets: -51.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.19
Quick Ratio: 11.18

Sales & Book Value

Annual Sales: $3.24 million
Price / Sales: 0.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.01 per share
Price / Book: 0.09

Miscellaneous

Outstanding Shares: 1,816,000
Free Float: 1,810,000
Market Cap: $2.18 million
Optionable: Optionable
Beta: 2.44

Social Links

Key Executives

Ken Berlin
President, Chief Executive Officer & Director

Igor Gitelman
VP-Finance, Chief Financial & Accounting Officer

Andres A. Gutiérrez
Chief Medical Officer & Executive Vice President

Michael Grace
Vice President-Technical Operations

Key Competitors

View All Competitors

ADXS Stock - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADXS shares.
View ADXS analyst ratings or view top-rated stocks.
How have ADXS shares performed in 2023?: Ayala Pharmaceuticals' stock was trading at $1.20 on January 1st, 2023. Since then, ADXS shares have increased by 0.0% and is now trading at $1.20.
View the best growth stocks for 2023 here.
Are investors shorting Ayala Pharmaceuticals?: Ayala Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,200 shares, an increase of 73.3% from the April 30th total of 3,000 shares. Based on an average daily trading volume, of 12,900 shares, the days-to-cover ratio is presently 0.4 days.
View Ayala Pharmaceuticals' Short Interest.
When is Ayala Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023.
View our ADXS earnings forecast.

How were Ayala Pharmaceuticals' earnings last quarter?: Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) issued its quarterly earnings results on Thursday, September, 9th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biotechnology company had revenue of $0.25 million for the quarter.
What is Ayala Pharmaceuticals' stock symbol?: Ayala Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ADXS."
How do I buy shares of Ayala Pharmaceuticals?: Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ayala Pharmaceuticals' stock price today?: One share of ADXS stock can currently be purchased for approximately $1.20.
How much money does Ayala Pharmaceuticals make?: Ayala Pharmaceuticals (OTCMKTS:ADXS) has a market capitalization of $2.18 million and generates $3.24 million in revenue each year. The biotechnology company earns $-14,360,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis.
How can I contact Ayala Pharmaceuticals?: Ayala Pharmaceuticals' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The official website for the company is www.advaxis.com. The biotechnology company can be reached via phone at (609) 452-9813, via email at ir@advaxis.com, or via fax at 609-452-9818.

This page (OTCMKTS:ADXS) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial